Page 62 - Boxed Warning News Today

Feeling of blacking out It’s important to take steps to capture these symptoms when you feel them. What were you doing? Were you standing or sitting? What time of day was it? A symptoms tracker may be helpful and serve as a tool to use when talking with your doctor. How is nOH Treated? There are a variety of lifestyle changes that may help ease the symptoms of nOH, like drinking two glasses of water, increasing your salt intake or wearing abdominal binders. In addition to lifestyle changes...

Share this article Share this article INDIANAPOLIS, May 4, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announces new initiatives to help COVID-19 patients in India as part of its commitment to bring the full force of its scientific and medical expertise to attack the coronavirus pandemic around the world. Lilly is offering donations of baricitinib to the Indian government through Direct Relief while simultaneously working with local Indian pharmaceutical companies to execute royalty-...

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19...

Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness Month New Outcomes Research in Patients With Schizophrenia or Bipolar I Disorder to be Presented Published 05-04-21 Submitted by Alkermes DUBLIN, May 4, 2021 /CSRwire/ -- Alkermes plc (Nasdaq: ALKS) recently announced plans to present clinical data and outcomes research from its psychiatry portfolio at three scientific conferences during Mental Health Awareness Month in...

DURECT Corporation Announces First Quarter 2021 Financial Results and Update of Programs Webcast of Earnings Call Today, May 4th at 4:30 p.m. ET News provided by Share this article Share this article CUPERTINO, Calif., May 4, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2021 and provided a corporate update. Q1 2021 Accomplishments: Initiated patient dosing in the Phase 2b AHFIRM clinical study of DUR-928 in severe...

Incyte logo. (PRNewsfoto/Eli Lilly and Company) INDIANAPOLIS, April 23, 2021 /PRNewswire/ -- Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple trials, Eli Lilly and Company (NYSE: LLY) and Incytes (NASDAQ:INCY) OLUMIANT ® (baricitinib) 2-mg tablet taken once daily showed improvement in key measured treatment outcomes compared to placebo, and helped further characterize the long-term safety profile in adults with moderate to severe at...

Ortho Dermatologics to Present New Data at the 2021 American Academy of Dermatology Annual Meeting News provided by Share this article ®, DUOBRII ® LAVAL, Quebec, April 21, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the presentation of six posters during the virtual American Academy of Dermatology (AAD) Annual Meeting, ...

Lilly and Incytes Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study - Results from two studies (BRAVE-AA1 and BRAVE-AA2) show statistically significant improvement in scalp hair regrowth across both baricitinib dosing groups, compared to placebo - Program data will support a submission to achieve a potential first-in-disease regulatory approval - Safety profile is consistent with the known safety findings for baricitinib News provided by Share this article ...

Alkermes Presents New Data From Psychiatry Portfolio at Virtual 2021 Congress of the Schizophrenia International Research Society - New Exploratory Analyses Presented From ENLIGHTEN-2 Study of LYBALVI™ in Patients With Schizophrenia - News provided by Share this article Share this article DUBLIN, April 20, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of new research from its psychiatry portfolio at the 2021 Congress of the Schizophrenia International Re...

(diroximel fumarate) reinforce the treatment’s positive gastrointestinal tolerability profile Biogen advances leading research to help inform future patient management including new information on the clinical profile of extended interval dosing with natalizumab CAMBRIDGE, Mass., April 16, 2021 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced new data from its industry-leading portfolio of multiple sclerosis (MS) therapies to be presented at the American Academy of Neurology...